Physician profile
Imran A Idrees
NPI 1922271204
$1,226.34
in general payments reported to CMS, 2019-2025
23 companies · $796 in 2025
The $796 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.40 · 2021: $80.84 · 2023: $23.78 · 2024: $241 · 2025: $796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $240.63 | 2019-2025 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $163.27 | 2025 | Enhertu, Vanflyta, Injectafer |
| Janssen Biotech, INC. | $90.63 | 2025 | Erleada, Rybrevant |
| Incyte Corporation | $72.80 | 2024-2025 | Jakafi, Niktimvo |
| Eisai INC. | $72.61 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $70.51 | 2025 | |
| Merck Sharp & Dohme LLC | $60.45 | 2024-2025 | Keytruda, Reblozyl |
| Gilead Sciences, INC. | $52.38 | 2021-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $47.44 | 2024-2025 | Fruzaqla |
| Genzyme Corporation | $45.38 | 2025 | |
| Pfizer INC. | $40.73 | 2024 | |
| Alexion Pharmaceuticals, INC. | $38.08 | 2024-2025 | Ultomiris |
| Aveo Pharmaceuticals, INC. | $30.01 | 2025 | |
| Celgene Corporation | $28.01 | 2025 | Reblozyl |
| Acrotech Biopharma INC. | $27.73 | 2025 | Beleodaq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $22.43 | 2024 | |
| Caris Mpi, INC. | $20.03 | 2025 | Mi Cancer Seek |
| Kite Pharma, INC. | $19.01 | 2025 | Yescarta |
| Genentech USA, INC. | $18.63 | 2025 | Polivy, Tecentriq Hybreza, Columvi |
| Sumitomo Pharma America, INC. | $18.48 | 2025 | Orgovyx |
| Geron Corporation | $18.08 | 2025 | Rytelo |
| Array Biopharma INC | $15.67 | 2024 | Mektovi, Tukysa, Braftovi |
| Novocure INC. | $13.35 | 2024 | Optune Lua (Novottf-200t) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imran Idrees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.